Trial Profile

A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Patients With B-Cell Non-Hodgkin Lymphoma

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 12 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Glofitamab (Primary) ; Golcadomide (Primary) ; Iberdomide (Primary) ; Mosunetuzumab (Primary) ; Obinutuzumab (Primary) ; Tocilizumab (Primary)
Indications Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
Focus Adverse reactions; Therapeutic Use
Sponsors Roche

13 Dec 2024 Planned End Date changed from 15 Jul 2028 to 7 Mar 2029.
13 Dec 2024 Planned primary completion date changed from 15 Jul 2026 to 7 Mar 2027.
30 Sep 2024 Planned number of patients changed from 125 to 121.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com